WHO warns of an incurable risk of gonorrhea

The World Health Organization (WHO) has warned against antibiotic resistance that is making gonorrhea worse and sometimes untreatable.

Dr. Teodora Wi, health officer of the Department of Reproductive Health and Research of WHO, said: "We are going to have a threat of irreparable gonorrhea in the future. Gonorrhea is a microbe. When we release a new antibiotic to treat gonorrhea, after a while the bacteria will become resistant to the disease, and there have been reports of resistance to drugs. In the final treatment regimen, it is cephalosporin and azithromycin , so we need to be more alert and have supportive and cooperative activities to resolve antibiotic resistance problems in gonorrhea.

Some countries, especially high-income countries, where supervision is best, are finding cases of gonorrhea that cannot be cured by all antibiotics. These cases may be just the tip of the iceberg because systems to diagnose and report incurable infections are lacking in lower-income countries. "

In some countries, cases of gonorrhea cannot be cured by all antibiotics.

In a published report of PLOS Medicine, Dr. Wi and colleagues note that about 78 million people suffer from gonorrhea each year, including 35.2 million in the Western Pacific region, 11.4. million in Southeast Asia, 11.4 million in Africa, 11 million in the Americas, 4.7 million in Europe and 4.5 million in the Eastern Mediterranean region.

According to the WHO Global Monitoring Program for Contraband Bacteria, data from 2009 to 2014 show that ciprofloxacin resistance spreads to 97% of countries reporting drug-resistant strains. In addition, 81% of countries reported increased resistance to azithromycin and 66% reported warnings of resistance to broad-spectrum cephalosporins (ESCs) - cefixime or ceftriaxone injection - are currently the last contraband treatment. Currently, in most countries, ESCs are the only antibiotics that are effective for treating gonorrhea. From this fact in 2016, WHO has released an update on the treatment of gonorrhea globally to recommend clinicians to use two types of antibiotics: ceftriaxone and azithromycin.

In an article published in PLOS, Dr. Balasegaram and colleagues sketched a roadmap for research and development to find new antibiotics for multi-resistance gonorrhea. There are 3 drugs under study: Solithromycin (Cempra Inc), Zoliflodacin (Entasis Therapeutics), Gepotidacin (GlaxoSmithKline). The research team is accelerating the research process with the desire to introduce at least one of the three drugs to the community.

"To control gonorrhea, we need new tools and systems for prevention, better treatment and early diagnosis," said Dr. Marc Sprenger, WHO's director of antibiotic resistance secretariat. more, fully monitor and report new infections, antibiotic use, resistance and treatment failure. '